Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)

被引：2
|
作者：
Petramala, Luigi [1 ]
Letizia, Claudio [1 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Unit Secondary Arterial Hypertens, Dept Translat & Precis Med, Viale Policlin 155, I-00185 Rome, Italy
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2020年 / 6卷 / 04期
关键词：
D O I：
10.1093/ehjcvp/pvaa035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：252 / 252
页数：1
相关论文
共 50 条
  • [1] Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients
    Acanfora, Domenico
    Ciccone, Marco Matteo
    Scicchitano, Pietro
    Acanfora, Chiara
    Casucci, Gerardo
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (03) : 135 - 136
  • [2] Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan
    Clements, Richard T.
    Vang, Alexander
    Fernandez-Nicolas, Ana
    Kue, Nouaying R.
    Mancini, Thomas J.
    Morrison, Alan R.
    Mallem, Krishna
    McCullough, Danielle J.
    Choudhary, Gaurav
    CIRCULATION-HEART FAILURE, 2019, 12 (11)
  • [3] Angiotensin II Receptor Blocker And Neprilysin Inhibitor Sacubitril/valsartan Attenuates Experimental Pulmonary Hypertension
    Clements, Richard T.
    Vang, Alexander
    Kue, Nouaying R.
    Mancini, Thomas
    Morrison, Alan R.
    McCullough, Danielle J.
    Mallem, Krishna
    Choudhary, Gaurav
    CIRCULATION, 2019, 140
  • [4] Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E-Deficient Mice
    Zhang, Hui
    Liu, Gangqiong
    Zhou, Wenping
    Zhang, Wenjing
    Wang, Kai
    Zhang, Jinying
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
    Javad Habibi
    Annayya R. Aroor
    Nitin A. Das
    Camila M. Manrique-Acevedo
    Megan S. Johnson
    Melvin R. Hayden
    Ravi Nistala
    Charles Wiedmeyer
    Bysani Chandrasekar
    Vincent G. DeMarco
    Cardiovascular Diabetology, 18
  • [6] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
    Habibi, Javad
    Aroor, Annayya R.
    Das, Nitin A.
    Manrique-Acevedo, Camila M.
    Johnson, Megan S.
    Hayden, Melvin R.
    Nistala, Ravi
    Wiedmeyer, Charles
    Chandrasekar, Bysani
    DeMarco, Vincent G.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [7] Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
    Dargad, Ramesh R.
    Prajapati, Mahesh R.
    Dargad, Rohit R.
    Parekh, Jai D.
    INDIAN HEART JOURNAL, 2018, 70 : S102 - S110
  • [8] Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril plus valsartan: A pharmacovigilance study
    Guion-Firmin, Julia
    Tessier, Samuel
    Lepelley, Marion
    Faillie, Jean-Luc
    Montastruc, Jean-Louis
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 (02) : 378 - 389
  • [9] Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
    Hui Zhang
    Gangqiong Liu
    Wenping Zhou
    Wenjing Zhang
    Kai Wang
    Jinying Zhang
    Scientific Reports, 9
  • [10] The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3
    Quagliariello, V.
    Bonelli, A.
    Paccone, A.
    Buccolo, S.
    Iovine, M.
    Rea, D.
    Cerrone, F.
    Botti, G.
    Maurea, N.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2836 - 2836
12345